Gene · 10203
CALCRL: calcitonin receptor like receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CALCRL: calcitonin receptor like receptor. Genes, record 10203. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10203
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16602 | Calcitonin gene-related peptide type 1 receptor | 461 | 25 | Ensembl, GeneID, HGNC |
Source UniProt
Patents86
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2025259600 A2 | 2025-12-18 | 15 | Q16602 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10914 | Q16602 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2003 | Q16602 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2004 | Q16602 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2005 | Q16602 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10914 | Q16602 | Espacenet |
| EP 4541896 A1 | 2025-04-23 | 271 | Q16602 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10508 | Q16602 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10510 | Q16602 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10511 | Q16602 | Espacenet |
1 to 10 of 86
See all 86 patentsDrugs13
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATOGEPANT | CHEMBL3991065 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| BI-44370 | CHEMBL3334624 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| DAVALINTIDE | CHEMBL2105635 | Calcitonin gene-related peptide type 1 receptor agonist | AGONIST | ChEMBL |
| ERENUMAB | CHEMBL3833329 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| MK3207 | CHEMBL1910936 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| OLCEGEPANT | CHEMBL207197 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| RIMEGEPANT | CHEMBL2178422 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| RIMEGEPANT SULFATE | CHEMBL2364629 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| TELCAGEPANT | CHEMBL236593 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
| UBROGEPANT | CHEMBL2364638 | Calcitonin gene-related peptide type 1 receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 13
See all 13 drugsTrials125
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07497854 | RIMEGEPANT SULFATE | ClinicalTrials.gov | ||
| NCT07475234 | RIMEGEPANT | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07301008 | RIMEGEPANT | PHASE4 | ClinicalTrials.gov | |
| NCT07159750 | RIMEGEPANT | ClinicalTrials.gov | ||
| NCT07159750 | ERENUMAB | ClinicalTrials.gov | ||
| NCT07159750 | ATOGEPANT | ClinicalTrials.gov | ||
| NCT07103694 | RIMEGEPANT | ClinicalTrials.gov | ||
| NCT07103694 | ERENUMAB | ClinicalTrials.gov | ||
| NCT07103694 | ATOGEPANT | ClinicalTrials.gov | ||
| NCT06999252 | RIMEGEPANT | PHASE2 | ClinicalTrials.gov |
1 to 10 of 125
See all 125 trialsNIH grants836
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CALCRL papers | Newest fiscal year |
|---|---|---|---|
| R01HD060860 | Adrenomedullin Signaling at the Maternal-Fetal Interface | 11 | 2025 |
| R01NS102722 | Endosomal Platforms for Signaling Pain | 4 | 2025 |
| T32GM136640 | Tri-institutional PhD Program in Chemical Biology | 4 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 3 | 2025 |
| R01DA012864 | Mechanisms and Cellular Function of Opioid Receptor Endocytosis | 3 | 2025 |
| T32HL069768 | Pre-doctoral Training Program in Integrative Vascular Biology | 3 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
| P01AG051459 | Competing Renewal P01 | 2 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 836Source NIH's project files
See all 836 nih grantsPapers1,370
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea. | Front Immunol | 2026 | 42751103 | PubTator, text mining | PubMed |
| The RAMP3 proximity interactor MYO6 determines spatiotemporal signaling of the GPCR CLR in lymphatic endothelial cells. | Sci Signal | 2026 | 42743267 | PubTator, text mining | PubMed |
| Druggable tumor-nerve-immune circuits in cancer pain: Model systems, human translatability and therapeutic paradoxes. | Pharmacol Res | 2026 | 42716238 | PubTator, text mining | PubMed |
| Metabolic and Candidate Genetic Factors Associated with Overweight/Obesity in Patients of Kazakh Ethnicity with Psoriasis: A Cross-Sectional Study. | Medicina (Kaunas) | 2026 | 42654346 | PubTator, text mining | PubMed |
| Integrated Gene-Metabolite Network Analysis Identifies Pathways Associated with Immune Regulation and Metabolic Remodeling in Subfertile Beef Heifers. | Genes (Basel) | 2026 | 42650082 | PubTator, text mining | PubMed |
| Multi-omics analyses reveal new insights into the genetic mechanisms of external genitalia erectile dysfunction in male geese. | Poult Sci | 2026 | 42526090 | PubTator, text mining | PubMed |
| Novel Role for CGRP in Aqueous Humor Outflow. | Invest Ophthalmol Vis Sci | 2026 | 42461077 | PubTator, text mining | PubMed |
| Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy. | Front Pharmacol | 2026 | 42460013 | PubTator, text mining | PubMed |
| Long-term treatment with Eptinezumab in special treatment situations: Real world data. | J Neurol Sci | 2026 | 42442067 | PubTator, text mining | PubMed |
| Machine learning-based integration develops a novel lysosome-related prognostic signature associated with prognosis and immune infiltration landscape in acute myeloid leukemia. | Discov Oncol | 2026 | 42334654 | PubTator, text mining | PubMed |
1 to 10 of 1,370
See all 1,370 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10203
GET https://conductscience.org/api/genes/v1/10203/patents?page=2